Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.74 USD | +8.07% | +40.32% | +47.46% |
Mar. 27 | ADRs End Higher; Connect Biopharma Holdings Climbs 21% | DJ |
Mar. 04 | HC Wainwright Starts Coverage on Connect Biopharma With Buy Rating, $7 Price Target | MT |
Strengths
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+47.46% | 95.82M | - | - | |
+2.73% | 108B | B+ | ||
+9.59% | 103B | B+ | ||
+6.58% | 23.48B | B | ||
-12.59% | 21.93B | B+ | ||
-3.29% | 19.68B | A- | ||
-35.36% | 18.37B | A- | ||
-13.29% | 16.33B | B | ||
+4.68% | 13.72B | C+ | ||
+34.25% | 12.15B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock
- Equities
- Stock Connect Biopharma Holdings Limited - Nasdaq
- Ratings Connect Biopharma Holdings Limited